购物车
- 全部删除
- 您的购物车当前为空
Ipilimumab 是全人类单克隆抗体 IgG1κ,能够抗 CTLA-4。其中CTLA-4是一种由活化的 T 细胞产生的免疫抑制分子。
为众多的药物研发团队赋能,
让新药发现更简单!
Ipilimumab 是全人类单克隆抗体 IgG1κ,能够抗 CTLA-4。其中CTLA-4是一种由活化的 T 细胞产生的免疫抑制分子。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 4,390 | 现货 | |
2 mg | ¥ 6,260 | 现货 | |
5 mg | ¥ 9,470 | 现货 | |
10 mg | ¥ 12,700 | 现货 | |
25 mg | ¥ 18,800 | 5日内发货 | |
50 mg | ¥ 25,300 | 5日内发货 |
产品描述 | Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. |
细胞实验 | Objective: Ipilimumab augments antitumor activity of bispecific antibody-armed T cells. Concentrations: 0, 0.5, 5.0, and 50 μg/mL. Incubation Time: 10-14 days. Method: hPBMC were stimulated with anti-CD3 monoclonal antibody with or without ipilimumab and expanded for 10-14 days. ATC were harvested and armed with anti-CD3 x anti-EGFR BiAb (EGFRBi) or anti-CD3 x anti-CD20 BiAb (CD20Bi) to test for redirected cytotoxicity against COLO356/FG pancreatic cancer cell line or Burkitt's lymphoma cell line (Daudi). |
动物实验 | Objective: To investigate whether Ipilimumab and PD-1 antibody enhance the ability of T cells to control the outgrowth of EBV-induced lymphomas. Formulation: PBS. Dosages: 100 μg, three times weekly |
别名 | 伊匹单抗 |
分子量 | 148 kDa |
CAS No. | 477202-00-9 |
密度 | no data available |
存储 | store at -20°C | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容